<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848796</url>
  </required_header>
  <id_info>
    <org_study_id>southlake</org_study_id>
    <nct_id>NCT00848796</nct_id>
  </id_info>
  <brief_title>Comparative Study of Two Brands of Heparin Already on the Market</brief_title>
  <official_title>Do Different Heparin Brands Influence Bleeding in Coronary Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southlake Regional Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southlake Regional Health Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Two heparin brands have been in the market in Canada for several years. Heparin Leo from Leo&#xD;
      Pharma and Hepalean from Organon. The former is standardized by B.P (British pharmacopeia)&#xD;
      while the latter is standardized by U.S.P (United states pharmacopeia). Previous studies have&#xD;
      shown Heparin Leo to have roughly a 10% less efficacy then Hepalean. It has also been&#xD;
      demonstrated that more protamine is required to reverse Heparin Leo. It is the investigators'&#xD;
      intention to study the post-operative effects of the two brands of heparin and whether one of&#xD;
      the two causes less bleeding after bypass surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study protocol attempts not to change the normal protocol for cardiac surgery too much.&#xD;
&#xD;
      The two different brands of heparin-Heparin Leo (Leo pharma) and Hepalean (Organon) are&#xD;
      randomized by the float perfusionist using the program research randomizer.A 50 ml syringe is&#xD;
      loaded with heparin for the Anesthesiologist and labelled. A 20 ml syringe is loaded with&#xD;
      heparin and thenn labelled. It is a double blinded trial with the surgeon and anesthetist not&#xD;
      knowing which brand heparin is being used. All cases are isolated Coronary Artery Bypass&#xD;
      Grafting (C.A.B.G) with no concomittant conditions. The following are the patients excluded&#xD;
      from the trial&#xD;
&#xD;
        1. RE-DO&#xD;
&#xD;
        2. COMBINATION PROCEDURE&#xD;
&#xD;
        3. VALVE REPAIR/REPLACEMENT&#xD;
&#xD;
        4. IABP-PRE/INTRA//POST-OP&#xD;
&#xD;
        5. CELL SAVER INTRA-OP&#xD;
&#xD;
        6. ANEMIA (70 g/L)/BLEEDING DISORDER eg:Jehovah's witness,hemophilia etc.&#xD;
&#xD;
        7. USE OF APROTININ&#xD;
&#xD;
        8. SMALL ADULT &lt; 50 KG&#xD;
&#xD;
        9. AORTIC SURGERY WITH/WITHOUT CIRC ARREST&#xD;
&#xD;
       10. EMERGENT PATIENT WITH HEART FAILURE&#xD;
&#xD;
      Heparin will be administered in the trial to elevate the A.C.T-Activated clotting time to 480&#xD;
      s and above and the heparin level to 300u/Kg to intiate cardio-pulmonary bypass (C.P.B).&#xD;
      Additional heparin will be given to maintain the above-mentioned levels.&#xD;
&#xD;
      The following data will be studied&#xD;
&#xD;
        -  BSA&#xD;
&#xD;
        -  Height&#xD;
&#xD;
        -  Weight&#xD;
&#xD;
        -  Diagnosis&#xD;
&#xD;
        -  Procedure&#xD;
&#xD;
        -  Surgeon&#xD;
&#xD;
        -  Anesthetist&#xD;
&#xD;
        -  Perfusionist&#xD;
&#xD;
      Pre pump Hb Pump Hb Post pump Hb&#xD;
&#xD;
      Pre pump ACT Pump ACT Post pump ACT&#xD;
&#xD;
      Projected heparin conc. Slope Protocol heparin conc Heparin time CPB time X-clamp time&#xD;
      Heparin (initial dose) Extra heparin on pump Prime Volume RAP Volume Pump balance ml Urine&#xD;
      output ml Average temp on CPB Phenylephrine Amt Levofed amt Creatinine AST Calculated&#xD;
      protamine dose at the end of the case Extra protamine given Total protamine CBC after pump&#xD;
      Total chest tube drainage in OR ml Total patient in OR time&#xD;
&#xD;
      Pre pump Post Pump Platelet INR PTT PT&#xD;
&#xD;
      Date Time NA Plavix stopped ASA stopped Heparin stopped Coumadin stopped&#xD;
&#xD;
      FFP given Total packed cells given Total platelets given Other factors given Other blood&#xD;
      product given Ca2+ given DDAVP given&#xD;
&#xD;
      Post-op 6 hrs 12 hrs 24 hrs Chest tube drainage (ml) Chest tube removed time Hct Platelet INR&#xD;
      PTT&#xD;
&#xD;
      ADDITIONS Packed cells Cryo Platelets Other blood product / factors&#xD;
&#xD;
      Chest reopening Yes No The reason if yes Patient transfer date- Time&#xD;
&#xD;
      Overall we are going to look at whether their is any impact on post-operative&#xD;
      bleeding,hospital and ICU stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chest tube drainage</measure>
    <time_frame>24 to 48 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of heparin used</measure>
    <time_frame>1 to 7 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Protamine used</measure>
    <time_frame>1 to 7 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured slope with heparin/ACT titration</measure>
    <time_frame>1 to 7 hrs</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Bypass Grafting</condition>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Compare two market brands of Heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin Leo and Hepalean</intervention_name>
    <description>Dosage based on Heparin does response curve obtained from the Medtronic HMS plus</description>
    <arm_group_label>Heparin</arm_group_label>
    <other_name>Heparin Leo</other_name>
    <other_name>Hepalean</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Isolated Coronary Artery Bypass Surgery&#xD;
&#xD;
          -  Normal Hematocrit&#xD;
&#xD;
          -  Normal Creatinine&#xD;
&#xD;
          -  Normal Liver function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Re-do&#xD;
&#xD;
          -  Combination procedure&#xD;
&#xD;
          -  Valve repair/replacement&#xD;
&#xD;
          -  IABP-pre/Intra/Post-op&#xD;
&#xD;
          -  Cell saver intra-op&#xD;
&#xD;
          -  Anemia (70 g/L)/Bleeding disorder, e.g.,: Jehovah's witness, hemophilia etc.&#xD;
&#xD;
          -  Use of aprotinin&#xD;
&#xD;
          -  Small adult &lt; 50 kg&#xD;
&#xD;
          -  Aortic surgery with/without circ. arrest&#xD;
&#xD;
          -  Emergent patient with heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles M Peniston, MD,FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiac surgery-S.R.H.C</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Dyck L, Friesen RM. Do different heparin brands influence activated clotting times? J Extra Corpor Technol. 1998 Jun;30(2):73-6.</citation>
    <PMID>10182116</PMID>
  </results_reference>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>February 19, 2009</last_update_submitted>
  <last_update_submitted_qc>February 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr CM Peniston</name_title>
    <organization>Southlake Regional Health Centre</organization>
  </responsible_party>
  <keyword>Heparin Leo</keyword>
  <keyword>Hepalean</keyword>
  <keyword>CPB Cardiopuilmonary Bypass</keyword>
  <keyword>CABG Coronary Artery Bypass Grafting</keyword>
  <keyword>Anticoagulation efficacy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

